Skip to main content

PotlatchDeltic (NASDAQ:PCH) Given "Sector Perform" Rating at Royal Bank of Canada

Tuesday, May 4, 2021 | MarketBeat

PotlatchDeltic (NASDAQ:PCH)'s stock had its "sector perform" rating restated by research analysts at Royal Bank of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $65.00 price objective on the real estate investment trust's stock, up from their prior price objective of $58.00. Royal Bank of Canada's price target suggests a potential upside of 8.39% from the company's current price.

Several other research analysts have also recently weighed in on the stock. Raymond James upped their price objective on shares of PotlatchDeltic from $61.00 to $79.00 and gave the stock a "strong-buy" rating in a research report on Monday. BMO Capital Markets cut shares of PotlatchDeltic from an "outperform" rating to a "market perform" rating and raised their target price for the stock from $58.00 to $65.00 in a report on Wednesday, April 28th. Finally, DA Davidson reaffirmed a "neutral" rating on shares of PotlatchDeltic in a research report on Tuesday, March 23rd. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company's stock. The company has an average rating of "Buy" and an average price target of $58.20.

PCH stock opened at $59.97 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 1.37 and a debt-to-equity ratio of 0.59. The company's 50 day moving average is $56.32 and its 200 day moving average is $50.61. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of 51.70 and a beta of 1.34. PotlatchDeltic has a 1-year low of $29.12 and a 1-year high of $63.99.

PotlatchDeltic (NASDAQ:PCH) last posted its quarterly earnings data on Sunday, April 25th. The real estate investment trust reported $1.94 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.76 by $0.18. The company had revenue of $354.20 million for the quarter, compared to analysts' expectations of $331.65 million. PotlatchDeltic had a net margin of 8.62% and a return on equity of 9.37%. PotlatchDeltic's revenue for the quarter was up 69.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) earnings per share. As a group, sell-side analysts forecast that PotlatchDeltic will post 2.88 EPS for the current fiscal year.

In related news, Director Michael J. Covey sold 18,293 shares of the business's stock in a transaction that occurred on Tuesday, February 16th. The stock was sold at an average price of $53.13, for a total value of $971,907.09. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric J. Cremers sold 6,568 shares of the business's stock in a transaction that occurred on Tuesday, February 16th. The stock was sold at an average price of $41.65, for a total value of $273,557.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 131,643 shares of company stock valued at $7,625,589. 3.00% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of PCH. Norges Bank purchased a new position in PotlatchDeltic in the 4th quarter worth approximately $44,605,000. BlackRock Inc. lifted its holdings in PotlatchDeltic by 4.5% in the 4th quarter. BlackRock Inc. now owns 8,351,900 shares of the real estate investment trust's stock worth $417,763,000 after purchasing an additional 361,809 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of PotlatchDeltic by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,133,622 shares of the real estate investment trust's stock worth $106,724,000 after acquiring an additional 205,392 shares in the last quarter. Morgan Stanley raised its holdings in shares of PotlatchDeltic by 316.1% during the 4th quarter. Morgan Stanley now owns 195,879 shares of the real estate investment trust's stock worth $9,798,000 after acquiring an additional 148,799 shares in the last quarter. Finally, Sirios Capital Management L P purchased a new stake in shares of PotlatchDeltic during the 4th quarter worth approximately $6,107,000. 82.55% of the stock is currently owned by institutional investors.

PotlatchDeltic Company Profile

PotlatchDeltic (NASDAQ:PCH) is a leading Real Estate Investment Trust (REIT) that owns 1.8 million acres of timberlands in Alabama, Arkansas, Idaho, Louisiana, Minnesota and Mississippi. Through its taxable REIT subsidiary, the company also operates six sawmills, an industrial-grade plywood mill, a residential and commercial real estate development business and a rural timberland sales program.

Featured Story: Golden Cross

Analyst Recommendations for PotlatchDeltic (NASDAQ:PCH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What are earnings reports?


7 Healthcare Stocks Delivering Innovation in 2021

We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.

Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.

However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.

That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.

View the "7 Healthcare Stocks Delivering Innovation in 2021".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.